Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study protocol for a randomized controlled trial

Massimo Antonelli, Clara Rosso-Fernández, José Garnacho-Montero, George Dimopoulos, José Miguel Cisneros, José Garnacho Montero, Paula Ramírez Gallmore, Juan Bonastre, Juan Carlos Montejo González, Ramón Ortiz Díaz-Miguel, Angel Estella García, Rafael Zaragoza Crespo, Rafael Sierra Camerino, Manuel Herrera Gutiérrez, Luis Alvarez-Rocha, Miguel Sanchez Garcia, Jose M. Allegue Gallego, Álvaro Castellanos Ortega, María Victoria De La Torre Prados, Ricard Ferrer RocaPablo Vidal Cortés, Apostolos Armaganidis, Serafim Nanas, Dimitrios Georgopoulos, Loannis Pneumatikos, George Nakos, George Baltopoulos, Antonia Koutsoukou, Epaminondas Zakynthinos, Militsa-Bitsani Papanikolaou, Apostolos Komnos, Monica Rocco, Roberto De Blasi, Andrea De Gasperi, V. Marco Ranieri-Francesco De Rosa, Edoardo De Robertis-Rosalba, Guarracino, Clara Rosso Fernández, Fernando Pérez Martínez, María Perales De Los Santos, Sophie Monteau, Antonio Gutierrez, Caridad Milara, M. Eugenia Pachón, Marina Pulido, Patricia Moreno, Mike Mcconnell, Fernando Pérez, Clementina López, Laureano García Cubiles, Juliana Martínez

Risultato della ricerca: Contributo in rivistaArticolo in rivista

13 Citazioni (Scopus)

Abstract

Ventilator-associated pneumonia (VAP) is one of the most common and severe hospital-adquired infections, and multidrugresistant gram-negative bacilli (MDR-GNB) constitute the main etiology in many countries. Inappropriate empiric antimicrobial treatment is associated with increased mortality. In this context, the empirical treatment of choice for VAP is unknown. Colistin, is now the antimicrobial with greatest in vitro activity against MDR-GNB.
Lingua originaleEnglish
pagine (da-a)102-102
Numero di pagine1
RivistaTrials
Volume16
DOI
Stato di pubblicazionePubblicato - 2015

Keywords

  • Anti-Bacterial Agents
  • Clinical Protocols
  • Colistin
  • Drug Resistance, Multiple, Bacterial
  • Europe
  • Gram-Negative Bacterial Infections
  • Humans
  • Incidence
  • Patents as Topic
  • Pneumonia, Ventilator-Associated
  • Research Design
  • Thienamycins
  • Time Factors
  • Treatment Outcome

Fingerprint

Entra nei temi di ricerca di 'Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study protocol for a randomized controlled trial'. Insieme formano una fingerprint unica.

Cita questo